A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS, in Patients With Hyperkalemia-HARMONIZE Global
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Therapeutic Use
- Acronyms HARMONIZE GL
- Sponsors AstraZeneca
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.
- 09 Dec 2016 Planned End Date changed from 1 Nov 2017 to 1 Feb 2018.
- 09 Dec 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Feb 2018.